Keybank National Association Ligand Pharmaceuticals Inc Transaction History

Keybank National Association

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 04, 2019	SELL	$86.25 - $120.16 $496,110 - $691,160	-5,752 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$107.38 - $129.34 $438,969 - $528,741	4,088 Added 245.67%	5,752 $657,000
Q1 2019 May 08, 2019	SELL	$105.93 - $142.47 $92,688 - $124,661	-875 Reduced 34.46%	1,664 $209,000
Q4 2018 Jan 30, 2019	BUY	$128.36 - $272.13 $9,113 - $19,321	71 Added 2.88%	2,539 $345,000
Q3 2018 Nov 08, 2018	SELL	$211.18 - $274.49 $27,875 - $36,232	-132 Reduced 5.08%	2,468 $677,000
Q2 2018 Aug 08, 2018	SELL	$150.77 - $207.98 $753 - $1,039	-5 Reduced 0.19%	2,600 $539,000
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $8,456 - $11,139	61 Added 2.4%	2,605 $430,000
Q4 2017 Feb 08, 2018	BUY	$128.36 - $147.04 $16,430 - $18,821	128 Added 5.3%	2,544 $348,000
Q3 2017 Nov 02, 2017	BUY	$120.91 - $137.94 $69,644 - $79,453	576 Added 31.3%	2,416 $329,000
Q2 2017 May 14, 2018	SELL	N/A	-427 Reduced 18.84%	1,840 $223,000
Q1 2017 May 14, 2018	BUY	N/A	2,267	2,267 $240,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.05B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

Stay updated on Keybank National Association with notifications on news.